Rare diseases
Investigational molecules
Locations
Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies
ItalyCarboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer
FranceEvaluation of belantamab mafodotin plus drug combination in adult patients with newly diagnosed light chain amyloidosis
GreeceA study of Cesnicabtagene autoleucel compared to a drug combination for patients with relapsed or refractory multiple myeloma
The NetherlandsA study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy
GermanyStudy of KYV-101, Fludarabine Phosphate, and Cyclophosphamide Monohydrate for Patients with Treatment-Resistant ANCA Vasculitis
GermanyStudy on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia
FranceStudy of Lisaftoclax and Acalabrutinib for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BulgariaStudy on Pembrolizumab and Cyclophosphamide for Patients with Metastatic Urothelial Cancer
ItalyStudy on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients
PolandStudy on Avacopan with Rituximab or Cyclophosphamide for Children Aged 6 to 17 with Active ANCA-associated Vasculitis
BelgiumStudy on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
